Researchers at Uppsala University, in Sweden, in collaboration with the SciLifeLab Drug Discovery and Development Platform, have taken “a large step forward” in developing a potential CAR T-cell therapy for glioblastoma, an aggressive form of brain cancer that is often difficult to treat.

Their project is now entering the final preclinical stage of development, according to the university. The goal is to start clinical studies within four years.

“Extremely few breakthroughs have been made around treating Glioblastoma,” Magnus Essand, professor of gene therapy at Uppsala, said in a press release.